At the news
? BULLISHIMPACT 6/10 8-K filed Nov 3, 2026 at 08:07 ET
Pfizer reported Q3 2026 adjusted diluted EPS of $0.87, beating the $0.73 consensus by 19.2%, on revenue of $16.58B versus the $15.88B estimate. The company raised full-year 2026 revenue guidance by $1.5B at the midpoint to $62.0-$64.0B and raised/narrowed adjusted EPS guidance to $2.95-$3.05, reflecting strong year-to-date performance and confidence in the business.
- Q3 2026 adjusted diluted EPS of $0.87 beat consensus of $0.73 by 19.2%
- Q3 2026 revenue of $16.58B was above the $15.88B consensus estimate
- Full-year 2026 revenue guidance raised by $1.5B at the midpoint to $62.0-$64.0B
- Full-year 2026 adjusted diluted EPS guidance raised and narrowed to $2.95-$3.05 from $2.80-$3.00
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access